StockData

BioHarvest Sciences vs Lexicon Pharmaceuticals

BHST and LXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BHST and LXRX compare

BioHarvest Sciences grew revenue faster over the last twelve months (37.0% versus −45.6% for Lexicon Pharmaceuticals).

BioHarvest Sciences keeps more of each dollar of sales as profit, with a net margin of −32.3% compared with −162% at Lexicon Pharmaceuticals.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBHSTLXRX
Size and price
Market cap–$796M
Share price$1.50$1.79
Change, 1 year−80.9%16.2%
Change, 5 years−86.1%−63.9%
Beta (5Y)0.871.76
Employees–81
StockData Score
Total score55
Valuation score00
Growth score2 (better)1
Performance score12 (better)
Health score22
Dividend score00
Valuation
P/S–20.7×
P/B–4.9×
Fair value–$0.871
Margin of safety–−106%
Growth
Revenue growth (TTM)37.0% (better)−45.6%
Revenue growth, 5Y average–15.7%
Profitability
Gross margin59.3%98.9% (better)
Operating margin−16.2% (better)−147%
Net margin−32.3% (better)−162%
FCF margin−27.8%–
Return on equity−83.2%−43.9% (better)
Return on invested capital−163%−140% (better)
Financial health
Debt / equity0.01 (better)0.32
Current ratio3.9710.63 (better)
Altman Z-score–−5.60
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–−8.9%
Shareholder yield–−8.9%
Ownership
Held by institutions7.4%81.9%
Held by insiders0.00%–
Insider net buying, 12 months–$2.8M
Short interest, % of float0.33%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.